Researchers have discovered the essential role of a new factor, LCOR, in enabling cancer cells to present tumor antigens on their surfaces. These antigens allow the immune system to recognize the tumor, an essential step if immunotherapy treatment is to succeed. On the other hand, they have shown that cancer stem cells have very low levels of LCOR, making them invisible to the immune system and therefore resistant to treatment.